Alterations of the structure and/or amount of glycans present on proteins are associated with many diseases. We previously demonstrated that changes in N-glycans alter Ab production. In the present study, we focused on the relationship between Alzheimer's disease (AD) and O-glycan, another type of glycan. The UDP-Nacetylgalactosamine:polypeptide N-acetylgalactosaminyltransferase (GalNAc-T) family functions in the first step of mucin-type O-glycan synthesis. Analysis of the expression of GalNAc-Ts in the human brain using real-time PCR revealed that the expression of several GalNAc-Ts was altered with sporadic AD progression. Three of these GalNAc-Ts (GalNAc-T1, GalNAc-T4 and GalNAc-T6) were transfected into HEK293T cells to examine their impact on Ab production. Transfection of GalNAc-T6 significantly reduced both Ab1-40 and Ab1-42 generation, but GalNAc-T1 and GalNAc-T4 only reduced Ab1-40 generation. Although these three GalNAc-Ts exhibited enzymatic activities on soluble amyloid precursor protein (APP), the GalNAc transferase activity of GalNAc-T6 to APP was most prominent. The expression of a-secretase and b-secretase was slightly altered in the transfected cells, but the activities of a-secretase and b-secretase were not significantly altered. These data suggest that excess O-glycosylation on APP by GalNAc-T6 inhibits Ab production.
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Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by neuronal loss and brain atrophy (1, 2) . The presence of extracellular senile plaques in the cerebral cortex and neurofibrillary tangle formation (NFT) are two major characteristics of AD pathology. The major component of senile plaques is b-amyloid (Ab), a cleaved fragment of amyloid precursor protein (APP). According to the 'amyloid cascade hypothesis', abnormal accumulation of Ab in the brain leads to neurodegenerative processes, finally resulting in neuronal death. Ab accumulation leads to NFT formation and subsequent neuronal loss and cognitive dysfunction (1, 2) . Therefore, APP proteolytic processing and Ab fragment formation are key steps in AD pathogenesis. Enzymes known as secretases cleave APP at different positions to generate smaller APP fragments. Cleavage of APP by a-secretase releases soluble APPa (sAPPa) fragments into the extracellular environment (a-cleavage occurs in the Ab domain of APP, preventing the generation of Ab, and is non-amyloidogenic). Conversely, the b-site APP-cleaving enzyme 1 (BACE1) cleaves APP and generates membrane-associated C99 and soluble APPb (sAPPb) fragments. Further cutting of C99 by g-secretase releases the Ab fragment. Approximately 90% of all Ab fragments generated are Ab1-40, but a smaller fraction is the more amyloidogenic Ab1-42 observed in amyloid plaques in the brain. Thus, among the products generated by the amyloidogenic (initially cut by b-secretase) and non-amyloidogenic (initially cut by a-secretase) pathways, only the amyloidogenic products are thought to lead to AD pathology.
APP undergoes several posttranslational modifications, including N-and O-glycosylation (35) . Proper glycosylation is necessary for the proper assembly and localization of proteins and for protection from proteolytic degradation. APP695, which is expressed primarily in neurons, has two N-glycosylation sites: Asn464 and Asn496. Changes in N-glycans have been shown to affect Ab generation (6, 7) . APP is also Oglycosylated mainly by sialylated O-glycans with a Core 1 structure (5). Core 1 type O-glycans are attached at Thr291, Thr292 and Thr576 of APP695 (8) . A number of other O-glycosylation sites have also been reported: Ser614, Ser623, Ser628, Thr633, Thr651, Thr652, Ser656, Thr663, Ser667, Ser679 and Ser697 have been detected in endogenous APP fragments in cerebrospinal fluid (corresponding to Ser539, Ser548, Ser553, Thr558, Thr576, Thr577, Ser581, Thr588, Ser592, Ser604 and Ser622 in APP695) (9, 10) . Interestingly, substitution of Ser124 on APP to eliminate O-glycosylation altered the localization of APP in the cell and decreased the generation of the intracellular C-terminal fragments of APP, Ab1-40 and Ab1-42 (4). These results indicate that APP cleavage by secretases occurs after O-glycosylation (4). APP is N-glycosylated in the ER and subsequently undergoes O-glycosylation in the Golgi apparatus (11) . In summary, O-glycosylated APP is cleaved by secretases, and O-glycosylation seems to play an important role in APP processing.
Here, we focused on the relationship between APP processing and mucin-type O-glycans. UDP-N-acetyl galactosamine:polypeptide N-acetylgalactosaminyltra nsferases (GalNAc-Ts) transfer GalNAc from UDPGalNAc to the hydroxyl group of a Ser or Thr residue of a polypeptide, the first step of mucin-type O-glycan synthesis (Fig. 1) . The GalNAc-T family is the largest glycosyltransferase family that forms a single glycosidic linkage (GalNAca1-Thr/Ser) and shows cell and organ-specific expression patterns (12) . However, the contributions and biological functions of individual GalNAc-Ts are poorly understood, and the differences in the peptide substrate specificities of each isozyme are not well understood. In this study, we examined the effects of mucin-type O-glycans on Ab formation and APP processing.
Experimental Procedures
Real-time RT-PCR analysis Human brain tissues were obtained from the Brain Bank for Aging Research (BBAR) as reported previously in (6) . The diagnosis of AD was based on the BBAR criteria (13, 14) and this study was approved by the Internal Review Board of Tokyo Metropolitan Institute of Gerontology and Tokyo Metropolitan Geriatric Hospital.
From a portion of each patient's brain, using the guanidinium thiocyanate method with TRIzol, total RNA was isolated (Thermo Fisher Scientific, Waltham, MA) and integrity of the RNA was confirmed by an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA). SuperScript II RNase H -Reverse Transcriptase and random primers (Thermo Fisher Scientific) were used to synthesize first-strand cDNAs from 5 mg of total RNA. TaqMan real-time RT-PCR assay on a 7300 Fast Real-Time PCR System (Thermo Fisher Scientific) were performed for relative quantification of the target mRNA following the manufacturer's instructions using the TaqMan Universal PCR Master Mix and TaqMan Gene Expression Assays: GalNAc-T1, Hs00234919_m1; GalNAc-T2, Hs00189537_m1; GalNAc-T3, Hs00237084_m1; GalNAc-T4, Hs00236809_s1; GalNAc-T5, Hs00294826_m1; GalNAc-T6, Hs00200529_m1, GalNAc-T7, Hs00213624_m1; GalNAc-T8, Hs00213610_m1; GalNAc-T9, Hs00222357_m1; GalNAc-T10, Hs00213903_m1; GalNAc-T11, Hs00254410_m1; GalNAc-T12, Hs00226436_m1; GalNAc-T13, Hs00287613_m1; GalNAc-T14, Hs00226180_m1; GalNAc-T15 (GalNAc-TL5), Hs00377152_m1; GalNAc-T16 (GalNAc-TL1), Hs00857466_m1; endogenous control, the TaqMan Ribosomal RNA Control Reagents VIC Probe. 18S rRNA was used as the normalization control.
Construction of expression vectors
The GalNAc-T4, GalNAc-T6 and human APP expression plasmids were purchased from OriGene Technologies (Rockville, MD). The GalNAc-T1 expression plasmid was purchased from Kazusa DNA Research Institute (Chiba, Japan). To construct the HA-tagged APP expression vector, human APP expression plasmid was used as the template for PCR amplification with the following primers: 5 0 -ACGATGT TCCAGATTACGCT-3 0 and 5 0 -AGCGTAATCTGGAACATCGT-3 0 . The PCR product encoding full-length APP with the HA-tag at the N-terminus was cloned into pcDNA3.1 Hygro (Thermo Fisher Scientific). Then, the ProSession protease (GE Healthcare, Buckinghamshire, England) sequence was inserted using the QuickChange site-directed mutagenesis system (Agilent Technologies, Santa Clara, CA) following the manufacturer's instruction with the following primers: 5 0 -CTGGAAGTTCTGTTCC AGGGGCCCCTGGAGGTACCCACTGATGG-3 0 and 5 0 -CCA TCAGTGGGTACCTCCAGGGGCCCCTGGAACAGAACTTC-CAG-3 0 . To construct the myc-tagged GalNAc-T expression vectors, human GalNAc-T expression plasmids were used as the template for PCR amplification with the following primers: 5 0 -ACGATGTTCCA GATTACGCT-3 0 and 5 0 -AGCGTAATCTGGAACATCGT-3 0 . The PCR product encoding full-length GalNAc-T and the myc-tag at the Cterminus was cloned into pcDNA3.1 Zeo (Thermo Fisher Scientific).
Cell culture and expression of GalNAc-T Human embryonic kidney (HEK) 293T cells were maintained in Dulbecco's modified Eagle's medium (Thermo Fisher Scientific) and supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml penicillin, and 50 mg/ml streptomycin at 37 C in a 5% CO 2 atmosphere. The expression plasmids were transfected into HEK293T cells using LipofectAMINE PLUS reagent (Thermo Fisher Scientific) according to the manufacturer's instructions. Stable transfectants were selected with hygromycin and zeocin (Thermo Fisher Scientific) at 5 mg/ml. The culture supernatants of these transfectants were collected after 24 h of incubation in Dulbecco's modified Eagle's medium:OptiMEM (1:1, v/v) supplemented with 0.2% fetal bovine serum. The cells were homogenized in 10 mM Tris-HCl, pH 7.4, 1 mM EDTA, 250 mM sucrose, 1 mM dithiothreitol and 1% protease inhibitor cocktail (Nacalai Tesque). After centrifugation at 900 Â g for 10 min, the supernatant was subjected to ultracentrifugation at 100,000 Â g for 1 h, and the precipitate was used as the microsomal fraction. The total protein concentration in each sample was determined by BCA assay (Thermo Fisher Scientific).
Western blot analysis
Proteins were separated by SDS-PAGE on a 7.5% gel and transferred to a PVDF membrane. The membrane was blocked in PBS containing 5% skim milk and 0.05% Tween 20 and incubated with Fig. 1 Scheme of mucin-type O-glycosylation by GalNAc-T. The first step of mucin-type O-glycosylation is the transfer of GalNAc from UDP-GalNAc to Ser or Thr residues, which is catalyzed by a polypeptide-N-acetylgalactosaminyltransferase (GalNAc-T). At least 20 GalNAc-Ts are encoded by different genes. GalNAc expression levels vary considerably between cell types and tissues. GalNAc is converted to Core 1 (Galb1, 3GalNAc) by a Core 1 b1, 3-galactosyltransferase termed T synthase or C1GalT-1. This activity is present in most cell types.
primary antibody. Anti-APP polyclonal antibody (22C11) was from Millipore (Billerica, MA), anti-APP monoclonal antibody (6E10) was from Signet laboratories (Dedham, MA), anti-sAPPa antibody and anti-HA antibody were from Abcam (Cambridge, England), anti-myc antibody was from Santa Cruz Biotechnology (Santa Cruz, CA), and anti-sAPPb antibody was from IBL (ImmunoBiological Laboratories, Gunma, Japan). The membrane was then incubated with secondary antibodies conjugated with horseradish peroxidase (GE Healthcare). Proteins that bound to the antibody were visualized with an ECL kit (Thermo Fisher Scientific). Secretases in the microsomal fractions were visualized after separation by SDS-PAGE using anti-TACE polyclonal antibody (QED Bioscience, San Diego, CA), anti-ADAM10 antibody and anti-BACE antibody (Abcam).
Lectin blot analysis
Proteins were treated with sialidase from Arthrobacter ureafaciens (Sigma-Aldrich Co., St Louis, MO), separated by SDS-PAGE, and transferred to a PVDF membrane. After blocking with 3% bovine serum albumin (BSA, Nacalai Tesque) in 10 mM Tris-HCl (pH 7.4) containing 140 mM NaCl, 1 mM CaCl 2 , 1 mM MgCl 2 , 1 mM MnCl 2 and 0.05% Tween 20 (TBS-T), the membrane was incubated with biotin-conjugated PNA (peanut agglutinin) from Arachis hypogaea or biotin-conjugated Vicia villosa agglutinin (VVA; Seikagaku Corporation, Tokyo, Japan) in TBS-T containing 1% BSA. After treating the membrane with a Vectastain ABC kit (Vector, Burlingame, CA), lectin-bound proteins were visualized by ECL. Quantification of soluble Ab by Sandwich ELISA Culture supernatants were subjected to an enzyme-linked immunosorbent assay (ELISA) using the Human Ab1-40 ELISA kit II and the Human Ab1-42 ELISA kit High Sensitive (Wako Pure Chemical Industries, Ltd., Osaka, Japan) according to the manufacturer's instructions.
Glycosidase treatment

GalNAc-T assay
The microsomal membrane fraction from transfected cells was used as the enzyme source to measure GalNAc-T activity. The enzyme assay mixture containing 40 mM sodium cacodylate buffer (pH 6.6), 250 mM UDP-[ 3 H]-GalNAc (160,000 dpm/nmol), 40 mM 2-mercaptoethanol, 10 mM MnCl 2 , 0.1% Triton X-100, 400 mM of peptide a (APP 568-587 , RPAADRGLTTRPGSGLTNIK) or peptide b (APP 586-
605
, IKTEEISEVKMDAEFRHDSG) and 40 mg of microsomal membrane fraction were incubated at 37 C for 4 h. After boiling for 3 min to stop the reaction, the mixture was subjected to reversed-phase HPLC with Mightysil RP-18GP Aqua column (2 Â 250 mm) (Kanto Chemical, Tokyo, Japan). Solvent A was 0.1% trifluoroacetic acid (TFA) in distilled water, and solvent B was 0.1% TFA in acetonitrile (MeCN). The peptide was eluted at a flow rate of 1 ml/min using a linear gradient of 150% solvent B. The peptide separation was monitored continuously at 214 nm, and the radioactivity of each fraction was measured using a liquid scintillation counter. sAPP was precipitated from the culture medium of APP-Vector-transfected cells with anti-HA agarose and subjected to the GalNAc-T assay as described above. The radioactivity of the reaction products was measured using a liquid scintillation counter.
For mass spectrometry (MS) analysis, the enzyme assay and product separation were performed following the same procedures described above with 250 mM UDP-GalNAc instead of UDP-[
3 H]-GalNAc.
MALDI-TOF MS(/MS) analysis
a-Cyano-4-hydroxycinnamic acid was dissolved at a concentration of 5 mg/ml in 50% MeCN containing 0.1% TFA; this solution was used as the matrix solution. The sample was dissolved in 10 ml of Milli-Q water, and 2 ml of this sample solution was mixed with 2 ml of the matrix solution. A 1-ml aliquot of this mixture was dropped onto a MALDI plate (Opti-TOF 384-Well Insert, AB SCIEX, Framingham, MA) and dried at room temperature. Mass spectra were acquired using an AB SCIEX TOF/TOF 5800 system (AB SCIEX)-operated using TOF/TOF Series-Explorer software version 4.1 (AB SCIEX). For each spot, MS spectra were acquired in positive ion mode between m/z 800 and 4,000 and accumulated from 1,000 laser shots in a randomized raster. MS/MS spectra were acquired using the following parameters and methods: acceleration voltage, 1 kV; CID control, OFF; laser shots, 4,000; precursor mass window, 200 resolution (FWHM); metastable suppression, ON.
Secretase assay
Secretase enzymatic assays were performed using the a-secretase assay kit and b-secretase assay kit (AnaSpec, Fremont, CA) according to the manufacturer's instructions. Briefly, cultured HEK293T cells were harvested, and the cell numbers were counted. The cells were lysed with extraction buffer and used as an enzyme source for the assay. An APP peptide conjugated to a fluorescent reporter and quencher was used as the substrate. The protein content of the cell lysates was determined by the BCA assay, and secretase activities were normalized to the protein concentration.
Statistical analysis
All data were plotted as the mean ± the SD. Statistical analysis was performed using one-way analysis of variance (ANOVA), followed by a Tukey test, Tukey-Kramer test or Games-Howell test (SPSS Statistics version 22.0, IBM, Armonk, NY); P50.05 was considered significant.
Results
GalNAc-T mRNA expression in the brains of AD patients
To investigate the expression levels of GalNAc-T in AD, we measured the amount of mRNA in the brains of AD patients using quantitative real-time RT-PCR (Fig. 2) . The mRNA expression levels of GalNAc-T4, GalNAc-T6, and GalNAc-T10 were significantly increased in eAD brains compared with controls (P = 0.013, 0.024, 0.039, respectively, Tukey test) and were increased even more in AD brains compared with controls (P = 0.013, 0.049, 0.001, respectively, Tukey test). By contrast, there were no statistically significant differences in GalNAc-T1, GalNAc-T2, GalNAc-T3, GalNAc-T12, GalNAc-T14, GalNAc-T15 and GalNAc-T16 mRNA levels (P > 0.05, Tukey test) with disease progression. The expression of GalNAc-T13 was higher in eAD brains but not in AD brains compared with controls (comparing control brains to eAD brains: P = 0.019; comparing controls to AD brains: P = 0.176, Tukey test). GalNAc-T7 and GalNAC-T8 exhibited higher expression in AD brains but not in eAD brains (comparing control brains to eAD brains: P = 0.095, 0.081, respectively; comparing controls to AD brains: P = 0.014, 0.026, respectively, Tukey test). mRNA expression of GalNAc-T5, GalNAc-T9 and GalNAc-T11 were not detected in this study. Notably, none of the GalNAc-T mRNAs were expressed at higher levels in the controls than in AD brains. These results suggest a possibility that some GalNAc-Ts may be associated with AD progression.
Establishment of APP and GalNAc-T co-expressing cells As described earlier, GalNAc-T1 exhibited similar expression levels in both controls and AD brains, and
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GalNAc-T4 and GalNAc-T6 were more highly expressed in eAD and AD brains than in controls. Based on these observations, we assumed that GalNAc-T4 and GalNAc-T6 levels might be related to Ab production and/or AD progression but GalNAc-T1 might not. To address this question, we constructed myc-tagged GalNAc-T expression plasmids (GalNAc-T1, GalNAc-T4 and GalNAc-T6) and co-transfected these plasmids with an HA-tagged APP plasmid into HEK293T cells. For each co-transfection, a stable transfectant was established (Fig. 3A) . HEK293T cells express GalNAc-T1 but not GalNAc-T4 or GalNAc-T6 (15) .
GalNAc-T and APP expression in the microsomal fractions and sAPP (soluble APP fragment) expression in the culture supernatant were determined by western blot (Fig. 3BD) . Myc-tagged GalNAc-Ts were expressed appropriately in each cell line. The anti-HA antibody recognized two APP forms in the microsomal fractions, one high-molecular-weight APP protein ($130 kDa) and one low-molecular-weight APP protein ($100 kDa) (Fig. 3C) . In contrast, sAPP in the culture supernatant showed only one band at $100 kDa (Fig. 3D) . N-glycosidase treatment slightly reduced the molecular weight of both bands in the microsomal fractions (Fig. 4, lanes 1 and 2) . Treatment with a combination of sialidase and O-glycosidase caused both the upper and lower bands to shift to a single band (Fig. 4, lane 3) . These results suggest that the high-molecular-weight APP proteins were N-and O-glycosylated and the low-molecularweight APP proteins were N-glycosylated, respectively. The presence of $100-kDa sAPP in the culture supernatant (Fig. 3D) suggests that sAPP is cleaved from the high-molecular-weight APP but not from the low-molecular-weight APP in the microsomal fractions. It was reported that APP is at first N-glycosylated and subsequently O-glycosylated. Thus, N-and O-glycosylated APP is cleaved by secretases (4, 7, 16) . Our results are consistent with these previous studies.
Effects of GalNAc-T expression on Ab Production
We then measured the levels of secreted Ab in the culture supernatant of the transfected cells (Fig. 5) . The concentrations of Ab1-40 and Ab1-42 secreted from the APP-Vector transfectant were 0.098 ± for GalNAc-T1, GalNAc-T4 and GalNAc-T6, respectively. These results indicate that increased cellular expression of GalNAc-T1, GalNAc-T4 and GalNAc-T6 led to a statistically significant reduction of Ab1-40 secretion. GalNAc-T1, GalNAc-T4 and GalNAc-T6 expression also downregulated Ab1-42 secretion, but only GalNAc-T6 resulted in a statistically significant reduction; the differences in expression induced by GalNAc-T1 and GalNAc-T4 did not reach statistical significance.
sAPP expressions APP is shed from the cells by a-secretase (a-cut) or bsecretase (b-cut), and its extracellular domain becomes the secreted form, sAPPa or sAPPb. To investigate the influence of excess O-glycosylation on APP shedding, sAPPa and sAPPb were detected by western blot analysis using anti-sAPPa and anti-sAPPb antibodies (Fig. 6A ). When compared with sAPP secreted from APP-Vector cells, the molecular weights of sAPP and sAPPa from GalNAc-T co-transfected cells were slightly higher, whereas the molecular weight of sAPPb was similar in all cells (Fig. 6A) . sAPPa in APP-T6 cells exhibited both an increased molecular weight and increased expression. Intriguingly, the level of sAPPb was extremely low in APP-T6 cells (Fig. 6A) . Furthermore, lectin blot analysis with PNA and VVA revealed that the reactivity of sAPP from GalNAc-T co-transfected cells with these lectins was stronger than that of sAPP from APP-Vector cells, particularly after sialidase treatment (Fig. 6B) . PNA binds to Galb1, 3GalNAc and VVA binds to GalNAc; both are used to detect O-glycosylation levels (17, 18) . VVA reacted with sAPP from GalNAc-T6 transfected cells without sialidase treatment. This result suggests that GalNAc-T6 increases O-GalNAcylation on Ser or Thr residues, but downstream enzymes that extend O-glycans, such as 
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ST6GalNAc-I and C1GalT-1, might not keep up with excess O-GalNAcylation.
Collectively, cells transfected with GalNAc-Ts, particularly GalNAc-T6, increased O-glycosylation of APP. Excess O-glycosylation inhibited production of sAPPb. These results are consistent with the decreased production of Ab in APP-GalNAc-T6 cells (Fig. 5) . NGlycosidase treatment of sAPP slightly reduced the size of the band (Fig. 6C) , similar to microsomal APPs (Fig. 4) . The size of sAPP decreased remarkably when it was treated with a combination of sialidase and O-glycosidase. The size of sAPP was similar in cells with or without GalNAc-T transfection after both N-and O-glycans were eliminated (Fig. 6D) . These results indicate that sAPP was both N-and O-glycosylated and that sAPP was derived from the upper band APP in Figure 3 . In addition, APP shedding efficiency by a-secretase (a-cut) or b-secretase (b-cut) was influenced by O-glycosylation. Taken together, these results indicate that GalNAc-T transfected cells have excessively O-glycosylated sAPP and that this excess O-glycosylation modulates APP processing.
GalNAc-T activities
The enzymatic activities of GalNAc-T1, GalNAc-T4, and GalNAc-T6 in the microsomal fraction were determined using sAPP and two peptides derived from APP695 (Fig. 7) . sAPP was immunoprecipitated from the APP-Vector cell culture supernatant and used as a substrate for the GalNAc-T assay. The amino acid sequences of the two APP peptides correspond to Arg568-Lys587 (peptide a) and Ile586-Gly605 (peptide b) of APP695. Peptide b contains the b-cut site in the middle of the peptide and has three potential O-glycosylation Ser/Thr sites. Peptide a shares two overlapping amino acids with peptide b and has four potential O-glycosylation sites. Thr651, Thr652, and Ser656 in APP770 (corresponding to Thr576, Thr577 and Ser581 in APP695) were previously reported to be O-glycosylated (10), indicating that not all potential Ser/Thr residues were glycosylated with O-GalNAc. When we measured the enzymatic activity of GalNAc-T1, GalNAc-T4, and GalNAc-T6 using sAPP as a substrate, GalNAc-T6 exhibited higher enzymatic activity than GalNAc-T1 and GalNAc-T4 (Fig. 7A) . GalNAc-T1 and GalNAc-T4 exhibited low but significant activity with sAPP. By contrast, for peptide a, GalNAc-T6 exhibited extremely high activity, GalNAc-T4 had very low activity, and GalNAc-T1 had no detectable activity (Fig. 7B) , even though GalNAc-T1 did exhibit moderate activity with sAPP. Interestingly, none of the GalNAc-Ts had activity with peptide b (Fig. 7B) . These results suggest that GalNAc-T1, GalNAc-T4, and GalNAc-T6 recognize APP as a substrate. However, these GalNAc-Ts did not glycosylate several Thr or Ser residues in APP with O-GalNAc because peptide b did not work as acceptor. sAPP prepared from APP-Vector cells may have already been partially O-glycosylated when secreted into the culture supernatant. Therefore, the activity of GalNAc-T6 with sAPP was lower than that with peptide a.
Analysis of O-GalNAcylated peptide a
To investigate the O-GalNAcylation sites on peptide a, which has four possible modification sites (three Thr and one Ser residues), MS and MS/MS analyses of OGalNAcylated peptide a were performed. Peptide a that was reacted with GalNAc-T6 was fractionated using reversed-phase HPLC, and the major products were recovered in fractions 6 and 7 (Fig. 8B) . Fractions 6 and 7 were then subjected to MS analysis. As shown + ion of peptide a without GalNAc, with one GalNAc, with two GalNAcs, and with three GalNAcs, respectively. The peak intensity of peptide a with one GalNAc was most abundant, and peptide a with four GalNAcs was not observed under our experimental conditions (Fig. 9A) . MS analysis of fraction 7 revealed that it was a mixture of peptide a without GalNAc and with one GalNAc (Fig. 9C) .
To identify the O-GalNAcylated site(s) of peptide a, the peak at m/z 2284.32 was subjected to MS/MS analysis (Fig. 9B) . The observed fragment ions (b- 
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and y-series) that matched the predicted ions within the 0.25-Da mass tolerance were labeled in the MS/MS spectrum and peptide sequence (Fig. 9B) . The two fragment ions at m/z 1242.52 (b10 ion) and 1346.59 (y11 ion) suggest that the Thr10 in the peptide a was modified with GalNAc. The fragment ion at m/z 1143.48 might also correspond to the y11 ion of peptide a modified with GalNAc at Thr9. However, neutral loss of 203 Da was observed in the MS/MS analysis, such as the fragment ion at m/z 1570.71 (y15-203), which did not match any possible fragment ions of peptide a with GalNAc at the Thr9. Additionally, the b9 ion with GalNAc was not observed. Based on these results, it is highly possible that fragment ion at m/z 1143.48 was a neutral loss of the y11 ion (y11-203). Consequently, the Thr10 in peptide a (RPAADRGLTTRPGSGLTNIK) was exclusively modified with GalNAc. These data indicate that the Thr10 in the peptide a was preferentially O-GalNAcylated by GalNAc-T6 over the remaining three Thr + Ser residues.
Secretase activities
As described above, GalNAc-T transfected cells exhibited reduced Ab generation. To elucidate the mechanism(s) responsible for reduced Ab generation, secretase expression levels and activities were measured. a-Secretase activity is mainly performed by two proteins: ADAM 10 (a disintegrin and metalloproteinase 10) and tumor necrosis factor-a converting enzyme (TACE or, equivalently, ADAM 17). TACE is reported to have immature and mature forms (1921). Western blot analysis of TACE revealed two major bands (Fig. 10A) . The upper band corresponds to immature TACE, and the lower band corresponds to mature TACE. Mature TACE levels decreased in APP-T4 and APP-T6 cells. ADAM10 is also reported to have immature and mature forms (22), although only the mature form was detected under our experimental conditions. APP-T6 cells exhibited modestly increased ADAM10 expression. BACE1 can be transformed from an immature form to a mature form (23, 24) . The two bands of BACE1 were nearly identical in all transfected cells (Fig. 10A) . The migration positions of TACE, ADAM10, and BACE1 were similar in GalNAc-T transfected cells and APP-Vector cells. Thus, GalNAc-T transfection affected the expression of secretases slightly, suggesting that the transfections may affect enzymatic activity.
To address this possibility, the a-and b-secretase activities of each transfectant were measured. As shown in Figure 10B , the a-secretase activities of GalNAc-T transfectants were similar to that of APPVector cells (92 ± 13.11, 94 ± 21.0 and 111 ± 9.17% of the activity of the APP-Vector transfectant in the GalNAc-T1, GalNAc-T4 and GalNAc-T6 transfectants, respectively). The b-secretase activities of the GalNAc-T transfectants were also not statistically significantly different (172 ± 51.73%, 127 ± 19.31 and 155 ± 52.6 of the APP-Vector transfectant in the GalNAc-T1, GalNAc-T4, and GalNAc-T6 transfectants, respectively). Thus, the reduction of Ab in GalNAc-T transfected cells was not due to changes in a-secretase and b-secretase activities.
Discussion
In this study, we analyzed the effect of O-glycans on APP processing and Ab generation. We focused on mucin-type O-glycosylation, which is initiated by a (1)).
Effect of O-glycosylation on APP processing large family of up to 20 homologous enzyme members (GalNAc-Ts). Quantitative real-time RT-PCR of GalNAc-Ts in human brains revealed that the expression of each GalNAc-T changed with AD progression. As shown in Figure 2 , the expression of GalNAc-T1, 2, 3, 12, 14, 15 and 16 did not differ between controls and AD patients, whereas the expression of GalNAc-T4, 6, 7, 8 and 10 increased with advancing AD stage. The cause of differences in individual GalNAc-Ts is not fully understood but is thought to be due to differential transcriptional regulation of each GalNAc-T and/or different expression levels of each GalNAc-T (12). GalNAc-Ts are reported to be expressed in neurons and glial cells in human brain (25, 26) . APP is also expressed in neurons and glial cells. It is unclear in this study that the increments of GalNAc-Ts occurred in neurons or other cells. Identification of localization of increased GalNAc-Ts is an important issue in the future. However, the changes in several GalNAc-Ts may be related to AD pathogenesis because differential expressions were observed in patients with an advanced stage of AD. Furthermore, the mechanism why GalNAc-Ts were increased in AD brain remains unclear. It is of interest whether Ab directly upregulates GalNAc-T expression in neurons and glial cells.
To examine the effects of mucin-type O-glycan changes on APP processing, GalNAc-T1, GalNAc-T4, and GalNAc-T6 were transfected into HEK293T cells. We selected these three GalNAc-T isozymes because GalNAc-T4 and GalNAc-T6 but not GalNAc-T1 exhibited increased expression during AD progression. These three GalNAc-Ts were expressed in the brain at different expression levels (Fig. 2) (2729) , and each GalNAc-T isozyme had different, albeit partly overlapping, peptide substrate specificities (12, 3032) . These characteristics suggest that each GalNAc-T may regulate distinct protein functions. Notably, GalNAc-T6 is highly homologous to GalNAc-T3 (29) . In this study, GalNAc-T6 mRNA levels were significantly increased in AD brains, whereas GalNAc-T3 levels were not (Fig. 2) , suggesting that even homologous proteins may play different pathological roles.
Intriguingly, all three GalNAc-Ts reduced Ab1-40 generation significantly and also reduced Ab1-42 generation, although only GalNAc-T6 produced a statistically significant difference in Ab1-42 generation (Fig. 5) . The reduced Ab production was not attributable to a reduction of b-secretase activity because bsecretase activity was not affected by the expression of GalNAc-Ts (Fig. 10) . Another possibility is that the effects of O-glycosylation on protein trafficking, localization and conformation (33, 34) may alter the susceptibility of proteins to secretases. As described above, a defect of APP O-glycosylation was altered the localization in the cells (4). It is known that BACE1 predominantly exists in intracellular acidic compartments like endosome or trans-Golgi (35) . Therefore, it is also possible that the OGalNAcylation by GalNAc-T6 may inhibit APP to be translocated to these compartments and thus Oglycosylation may affect Ab generation.
The amount of sAPPb in the culture supernatant was significantly downregulated in GalNAc-T6 expressing cells and GalNAc-T4 expressing cells (Fig. 6A ). By contrast, the amounts of sAPPa produced by these cells were increased. Moreover, the molecular weights of these fragments were increased compared with the controls, indicating that GalNAc-T6 and GalNAc-T4 increased the O-glycosylation level of APP. Consistent with this finding, all APP proteins derived from different cells had the same molecular weight after glycosidase digestion (Fig. 6D) . In in vitro enzymatic studies (Fig. 7A) , APP was an acceptor for GalNAc-T6. Taken together, these data suggest that the O-glycosylation level of APP may regulate its susceptibility to a-secretase and/or b-secretase. HEK293T cells do not express GalNAc-T4 or GalNAc-T6 but do express GalNAc-T1 (15) . Although sAPP was more poorly accepted by GalNAc-T1 than GalNAc-T6, it is possible that potential O-GalNAc sites on recombinant sAPP were already modified by endogenous GalNAc-T1 intracellularly because the sAPP used in this study was prepared from the supernatant of a HEK293T cell culture.
The importance of site-specific O-glycosylation in ectodomain shedding of cell membrane proteins has recently been reported in (36) . Additionally, previous studies have suggested that O-glycosylation may serve as a specific cleavage signal, and dysregulation of protein cleavage is thought to be involved in a variety of diseases (3742). Ser124 is necessary for appropriate Oglycosylation and trafficking of APP to the secretory pathway, and substitution of Ser124 diminishes APP cleavage by both a-secretase and b-secretase (4). Clearly, O-glycosylation affects the destiny of APP protein and AD pathogenesis. Our data suggest that enhanced O-glycosylation prioritizes cutting at the asite in the APP trafficking pathway, which then induces the reduction of Ab generation. Although several GalNAc-Ts as well as GalNAc-T6 were upregulated in AD brain (Fig. 2) , it is unclear how these GalNAcTs reduced Ab production. It may be caused by cellspecific difference of GalNAc-Ts expression as described already. In addition, it may be due to the substrate-specific difference of individual GalNAc-T (12). It is important to elucidate the detailed relationship between O-glycosylation level and Ab production in the future.
Finally, we determined that sAPP is accepted as a substrate by GalNAc-T6 and that Thr10 in peptide a (corresponding to Thr577 of APP695) is preferentially O-GalNAcylated by GalNAc-T6 (Fig. 9) . Previously, Thr576 of APP695 expressed in CHO cells was modified by an O-glycan (8). However, Thr576, which corresponds to Thr9 in peptide a, was not GalNAcylated by GalNAc-T6 in the present study. The reason for this discrepancy remains unclear but may include differences in cell types (CHO vs HEK293); differences in substrates (APP versus peptides), and differences in the assay system (in vivo versus in vitro, i.e. Thr576 may be GalNAcylated by other GalNAc-Ts but not GalNAc-T6, 4 or 1). Both Thr651 and Thr652 in APP770 (corresponding to Thr576 and Thr577 of APP695) are modified by O-GalNAc (9, 10, 43), although it is unclear whether these amino acid residues are also OGalNAcylated in APP695. Modification of specific O-glycan-sites by GalNAc-T6 appears to affect the regulation of the APP proteolytic cleavage pathway.
A single nucleotide polymorphism (SNP) at Ala673 in APP770 (corresponding to Ala598 of APP695) has been identified in elderly people without AD. The amino acid substitution of Ala for Thr induced by this SNP provides a new potential O-glycosylation site. This mutant APP results in a reduction of Ab production by 40% (44, 45) , suggesting that O-glycosylation at Thr673 inhibits shedding by BACE1 or promotes TACE activity. Similar regulatory mechanisms may be elicited by excess O-glycosylation by GalNAc-T overexpression. Src activation induces the redistribution of GalNAc-T from the Golgi to the ER, resulting in a higher density of GalNAc modifications on proteins (46) . If these modifications also occur on the APP protein, it may effectively increase O-glycosylation on APP and lead to reduced Ab generation.
We initially thought the increase in GalNAc-T6 expression in eAD and AD might be related to an enhancement of Ab production in AD progression. Surprisingly, our data suggested the opposite, and we observed that excess O-glycosylation on APP by GalNAc-T6 significantly reduced Ab production. The excess O-glycosylation on APP by GalNAc-T6 may have altered the susceptibility of APP to secretases and not the activities of the secretases themselves. Although further study is needed to reveal the mechanism, O-glycan pathway modifications that enhance cleavage by a-secretase and/or inhibit cleavage by b-secretase may be a possible target for future therapeutics.
